Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C19 | P33261 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.35 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | MMP1 | P03956 | 1/20 | 0.32 |
| ▸ | MMP9 | P14780 | 1/20 | 0.32 |
| ▸ | MMP13 | P45452 | 1/20 | 0.32 |
| ▸ | PKM | P14618 | 1/20 | 0.32 |
| ▸ | HTT | P42858 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3348790 | 0.81 | ALDH1A1 (0.37) | CYP2C19MAPTALDH1A1LMNAPKM | |
| SCHEMBL27412775 | 0.80 | MAPT (0.41) | CYP2C19MAPTPOLBTDP1DGAT1 | |
| Ammonia Solution, Strong SCHEMBL16982684 | 0.78 | MAPT (0.40) | CYP2C19MAPTPOLBTDP1DGAT1 | |
| SCHEMBL3181055 | 0.78 | CYP2C19 (0.38) | CYP2C19MAPTPOLBTDP1DGAT1 | |
| SCHEMBL631049 | 0.78 | CYP2C19 (0.38) | CYP2C19MAPTPOLBTDP1DGAT1 | |
| SCHEMBL6450503 | 0.78 | MAPT (0.38) | CYP2C19MAPTPOLBTDP1DGAT1 | |
| SCHEMBL17666352 | 0.77 | ALDH1A1 (0.38) | CYP2C19MAPTPOLBTDP1DGAT1 | |
| Ammonia Solution, Strong SCHEMBL16895224 | 0.77 | CYP2C19 (0.37) | CYP2C19MAPTPOLBTDP1DGAT1 | |
| SCHEMBL629663 | 0.77 | ALDH1A1 (0.38) | CYP2C19MAPTPOLBTDP1DGAT1 | |
| SCHEMBL1361079 | 0.76 | CYP2C19 (0.39) | CYP2C19MAPTPOLBTDP1DGAT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130338141-A1 | HIV INTEGRASE INHIBITORS | ISAACS RICHARD C (US) | 2013-12-19 | — | — | US | disclosed |
| US-8513234-B2 | HIV integrase inhibitors | MERCK SHARP & DOHME CORP. (US) | 2013-08-20 | — | — | US | disclosed |
| US-8513234-B2 | HIV integrase inhibitors | MERCK SHARP & DOHME CORP. (US) | 2013-08-20 | — | — | US | disclosed |
| US-8513234-B2 | HIV integrase inhibitors | MERCK SHARP & DOHME CORP. (US) | 2013-08-20 | — | — | US | disclosed |
| EP-2349276-A2 | HIV INTEGRASE INHIBITORS | Merck Sharp & Dohme Corp. (US) | 2011-08-03 | — | — | EP | disclosed |
| WO-2010042392-A2 | HIV INTEGRASE INHIBITORS | MERCK & CO., INC. (US) | 2010-04-15 | — | — | WO | disclosed |
| WO-2010042391-A2 | HIV INTEGRASE INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2010-04-15 | — | — | WO | disclosed |
| WO-2010042391-A2 | HIV INTEGRASE INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2010-04-15 | — | — | WO | disclosed |
| US-20100087419-A1 | HIV INTEGRASE INHIBITORS | MERCK SHARP & DOHME LLC | 2010-04-08 | — | — | US | disclosed |
| US-20100087419-A1 | HIV INTEGRASE INHIBITORS | MERCK SHARP & DOHME LLC | 2010-04-08 | — | — | US | disclosed |
| US-20100087419-A1 | HIV INTEGRASE INHIBITORS | MERCK SHARP & DOHME LLC | 2010-04-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130338141-A1 | HIV INTEGRASE INHIBITORS | POLB, CCNB1, POLR2A | CYP2C19 788/4885MAPT 1402/4885POLB 1/4885 |
| US-20100087419-A1 | HIV INTEGRASE INHIBITORS | POLB, CCNB1, POLR2A | CYP2C19 788/4885MAPT 1402/4885POLB 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.